The Company's non-GAAP measures exclude charges related to stock-based compensation, amortization of acquired intangible assets and inventory step-up, impairment charges, technology licenses, restructuring charges and exit costs which include costs for personnel whose positions have been eliminated as part of a restructuring or are in the process of being eliminated, severance costs associated with the former CEO, accruals for and proceeds received from dispute resolutions and patent litigation, merger and acquisition and related integration costs, certain income tax benefits and credits, certain warranty charges, net change in the fair value of contingent consideration, the write-down of deferred revenue under business combination accounting, and related income tax effects on certain excluded items. The Company excludes these items primarily because they are significant special expense and gain estimates, which management separates for consideration when evaluating and managing business operations. The Company's management uses non-GAAP net income and non-GAAP earnings per share to evaluate its current operating results and financial results and to compare them against historical financial results. Additionally, we disclose below the non-GAAP measure of free cash flow, which is derived from our net cash provided (used) by operations, less purchases of fixed assets and IP, plus proceeds from the sale of IP. Management believes these non-GAAP measures are useful to investors because they are frequently used by securities analysts, investors and other interested parties in evaluating the Company and provides further clarity on its profitability.
In addition, the Company believes that providing investors with these non-GAAP measurements enhances their ability to compare the Company's business against that of its many competitors who employ and disclose similar non-GAAP measures. However, the manner in which we calculate these non-GAAP financial measures may be different from non-GAAP methods of accounting and reporting used by the Company's competitors to the extent their non-GAAP measures include or exclude other items. The material limitation associated with the use of the non-GAAP financial measures is that the non-GAAP measures may not reflect the full economic impact of Exar's activities. Accordingly, investors are cautioned not to place undue reliance on non-GAAP information. The presentation of this additional information should not be considered a substitute for net income or net income per diluted share or other measures prepared in accordance with GAAP.
EXAR CORPORATION AND SUBSIDIARIES | |||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||
(In thousands, except per share amounts) | |||||||||
(Unaudited) | |||||||||
|
|
|
|
|
|
|
|
|
|
|
THREE MONTHS ENDED |
|
TWELVE MONTHS ENDED | ||||||
|
MARCH 27, |
|
DECEMBER 27, |
|
MARCH 29, |
|
MARCH 27, |
|
MARCH 29, |
|
2016 |
|
2015 |
|
2015 |
|
2016 |
|
2015 |
|
|
|
|
|
|
|
|
|
|
Net sales |
$ 29,492 |
|
$ 29,013 |
|
$ 33,805 |
|
$ 113,587 |
|
$ 125,791 |
Net sales, related party |
7,283 |
|
8,426 |
|
10,052 |
|
35,791 |
|
36,259 |
Total net sales |
36,775 |
|
37,439 |
|
43,857 |
|
149,378 |
|
162,050 |
|
|
|
|
|
|
|
|
|
|
Cost of sales: |
|
|
|
|
|
|
|
|
|
Cost of sales (1) |
16,353 |
|
16,261 |
|
19,012 |
|
64,662 |
|
71,139 |
Cost of sales, related party |
3,082 |
|
4,025 |
|
3,951 |
|
15,929 |
|
14,359 |
Amortization of purchased intangible assets and inventory step-up costs |
2,462 |
|
2,461 |
|
2,525 |
|
9,884 |
|
11,740 |
Restructuring charges and exit costs |
105 |
|
- |
|
1,213 |
|
845 |
|
7,597 |
Proceeds from legal settlement |
- |
|
- |
|
- |
|
(1,500) |
|
- |
Impairment of intangibles |
- |
|
- |
|
- |
|
- |
|
8,367 |
Reversal of warranty reserve |
- |
|
- |
|
(792) |
|
- |
|
(1,078) |
Total cost of sales |
22,002 |
|
22,747 |
|
25,909 |
|
89,820 |
|
112,124 |
Gross profit |
14,773 |
|
14,692 |
|
17,948 |
|
59,558 |
|
49,926 |
Operating expenses: |
|
|
|
|
|
|
|
|
|
Research and development (2) |
7,197 |
|
7,230 |
|
8,534 |
|
31,403 |
|
37,181 |
Selling, general and administrative (3) |
9,570 |
|
10,280 |
|
10,291 |
|
39,235 |
|
43,758 |
Restructuring charges and exit costs |
96 |
|
2,228 |
|
537 |
|
3,646 |
|
4,589 |
Merger and acquisition costs |
- |
|
- |
|
393 |
|
- |
|
7,348 |
Impairment of intangibles |
- |
|
1,807 |
|
539 |
|
1,807 |
|
4,456 |
Net change in fair value of contingent consideration |
- |
|
- |
|
- |
|
- |
|
(4,343) |
Total operating expenses |
16,863 |
|
21,545 |
|
20,294 |
|
76,091 |
|
92,989 |
Loss from operations |
(2,090) |
|
(6,853) |
|
(2,346) |
|
(16,533) |
|
(43,063) |
|
|
|
|
|
|
|
|
|
|
Other income and expense, net: |
|
|
|
|
|
|
|
|
|
Interest income and other, net |
74 |
|
(7) |
|
16 |
|
34 |
|
571 |
Interest expense |
(42) |
|
(69) |
|
(56) |
|
(212) |
|
(1,082) |
Impairment of long term investment |
- |
|
- |
|
(509) |
|
- |
|
(544) |
Total other income and expense, net |
32 |
|
(76) |
|
(549) |
|
(178) |
|
(1,055) |
|
|
|
|
|
|
|
|
|
|
Loss before income taxes |
(2,058) |
|
(6,929) |
|
(2,895) |
|
(16,711) |
|
(44,118) |
Provision for (benefit from) income taxes |
124 |
|
208 |
|
19 |
|
(685) |
|
889 |
|
|
|
|
|
|
|
|
|
|
Net loss before noncontrolling interest |
(2,182) |
|
(7,137) |
|
(2,914) |
|
(16,026) |
|
(45,007) |
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable to noncontrolling interest |
- |
|
- |
|
- |
|
- |
|
(37) |
|
|
|
|
|
|
|
|
|
|
Net loss attributable to Exar |
$ (2,182) |
|
$ (7,137) |
|
$ (2,914) |
|
$ (16,026) |
|
$ (44,970) |
|
|
|
|
|
|
|
|
|
|
Net loss per share: |
|
|
|
|
|
|
|
|
|
Basic |
$ (0.04) |
|
$ (0.15) |
|
$ (0.06) |
|
$ (0.33) |
|
$ (0.95) |
Diluted |
$ (0.04) |
|
$ (0.15) |
|
$ (0.06) |
|
$ (0.33) |
|
$ (0.95) |
|
|
|
|
|
|
|
|
|
|
Shares used in the computation of net loss per share: |
|
|
|
|
|
|
|
|
|
Basic |
48,523 |
|
48,386 |
|
47,516 |
|
48,240 |
|
47,253 |
Diluted |
48,523 |
|
48,386 |
|
47,516 |
|
48,240 |
|
47,253 |
|
|
|
|
|
|
|
|
|
|
(1) Stock-based compensation included in cost of sales |
$ 103 |
|
$ 104 |
|
$ 122 |
|
379 |
|
$ 1,105 |
(2) Stock-based compensation included in R&D |
293 |
|
269 |
|
537 |
|
1,216 |
|
2,661 |
(3) Stock-based compensation included in SG&A |
754 |
|
669 |
|
2,006 |
|
3,986 |
|
9,848 |